Sentences with phrase «cells from patients at»

The team is currently working on genome sequencing of individual circulating tumour cells from patients at the Vancouver Prostate Centre.

«In theory, we could model progression of the disease by reprogramming skin cells from patients at a range of ages, including before symptoms begin.

One method is to remove some tumour cells from the patient at the time of surgery, insert a gene for an immune - stimulating protein into them, and return them to the body.

Not exact matches

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

«But at some point we'll be able fabricate a biodevice from a patient's own cells that will duplicate the most important functions of a kidney and that won't be rejected by the patient's immune system.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

According to Science Daily, Dr. Nagy, senior investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, there is a «new method of generating stem cells that does not require embryos as starting points and could be used to generate cells from many adult tissues such as a patient's own skin cells.»

At an early stage of development, the miniature organs grown from autistic patients» stem cells also showed faster cell division rates than those grown from the cells of non-autistic relatives.

His lab differentiates iPSCs from autistic patients into neurons and glial cells, which they suspect may be releasing cytokines at levels higher than normal in autistic patients.

In collaboration with Anna Pyle, Howard Hughes Medical Institute investigator and professor in the Department of Molecular, Cellular and Developmental Biology at Yale, Patrizio and his team studied samples from 20 cumulus cells in 15 patients younger than age 35 and in those age 40 and older.

The decision was seen as an effort to mollify the religious fundamentalists at the core of Bush's political support who are ideologically opposed to deriving the cells from frozen embryos in fertility clinics and scientists and patients who hope that the cells could be used to help patients with Parkinson's, Alzheimer's, spinal - cord injuries, and diabetes.

Now, doctors at the University of Kiel in Germany have neatly bypassed the initial bone removal procedure and instead grown the required bone from stem cells in the patient's own bone marrow.

They isolated blood cells from HIV - positive patients on antiretroviral therapy and at different stages of disease progression, as well as cells from non-infected individuals.

In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.

Based on these ex vivo experiments (in cells isolated from patients and then exposed to PD - L1 blocking agents outside of the body), they predict that when actual patients are given PD - L1 blocking agents, their viral load at the time will influence the «net» outcome, i.e., whether the blockage boosts or weakens the overall anti-HIV immune response.

HBI member V. Wee Yong, PhD and research associate Susobhan Sarkar, PhD, and their team including researchers from the Department of Clinical Neurosciences and the university's Southern Alberta Cancer Research Institute, looked at human brain tumor samples and discovered that specialized immune cells in brain tumor patients are compromised.

Lu's team will extract immune cells called T cells from the blood of the enrolled patients, and then use CRISPR — Cas9 technology — which pairs a molecular guide able to identify specific genetic sequences on a chromosome with an enzyme that can snip the chromosome at that spot — to knock out a gene in the cells.

Mice transplanted with cells grown from a patient suffering from Huntington's disease (HD) develop the clinical features and brain pathology of that patient, suggests a study published in the latest issue of Acta Neuropathologica by CHA University in Korea, in collaboration with researchers at Université Laval in Québec City, Canada.

Today's findings augment recent research also published in Nature (Dec. 7, 2016) detailing the team's development of a «stemness biomarker» — a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.

Researchers at Dana - Farber / Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only.

To test the platform, they obtained skin cells from consenting patients at the Center for Duchenne Muscular Dystrophy, all of whom had mutations that fell within the dystrophin gene hot spot.

In addition to looking at mouse models of diabetes, the researchers also showed that exposure of human pancreatic islet cells — both from healthy donors and from patients with Type 1 diabetes — to fasting - mimicking diet in a dish stimulated insulin production.

«If you do this enough times, and deplete the pool of latently infected cells, you could potentially cure patients from infection,» says Eric Verdin, a senior investigator at the Gladstone Institute of Virology and Immunology at the University of California, San Francisco.

Some of the experiments included cells from SMA patients, obtained through a collaboration with Han Phan, MD, a pediatric neurologist at Children's Healthcare of Atlanta, and the Laboratory for Translational Cell Biology at Emory.

In the next phase of the study, researchers will genetically sequence tumor cells from at least 500 patients and follow the course of their disease.

In a process called cellular reprogramming, researchers at Icahn School of Medicine at Mount Sinai have taken mature blood cells from patients with myelodysplastic syndrome (MDS) and reprogrammed them back into iPSCs to study the genetic origins of this rare blood cancer.

Last week, scientists at Harvard University and Columbia University announced that they had proved the viability of a new way to study a disease — amyotrophic lateral sclerosis — by reprogramming cells from a patient to become pluripotent stem cells, which can then become any type of cell or tissue.

«Cartilage cells (or chondrocytes) isolated and expanded from cartilage tissue have great potential as a cell - based therapy for patients with, for example, traumatic cartilage defects,» says Juha Piltti, doctoral student at the Department of Integrative Medical Biology.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Preventing this from happening is a specific responsibility of health authorities and governments worldwide to make sure that the hope and trust of patients are not misused,» remarked Elena Cattaneo, Director of the Centre for Stem Cell Research at the University of Milan, Italy, and one of the scientists who contributed to the commentary.

Clinical trials that charge enrollees to participate are ostensibly aimed at giving patients early access to promising therapies — often in the fields of stem cells or aging reversal — that are too unusual or have too little profit potential to get funding from traditional sources such as companies, foundations, or the National Institutes of Health.

Researchers in Keele University's Research Institute for Science and Technology in Medicine and at the Haywood Rheumatology Centre, in Staffordshire, UK, and the University Hospitals of North Midlands NHS Trust, have for the first time identified disease - associated changes to the DNA epigenome in joint fluid cells from patients with rheumatoid arthritis.

Fine got federal approval this year to try such a drug screen on one patient whom he describes as «well - connected,» creating an organoid from her cells and adding bits of her tumor to it in hopes of throwing drug after drug at it until one vanquished the organoid's cancer.

Moreover, in collaboration with Prof Dr Henrik Milting at the Heart and Diabetes Center in Bad Oeynhausen, the researchers from Bochum analysed isolated myocardial cells from explanted hearts of patients.

After running the simulations at IU Bloomington, Bacallao confirmed the cyst growth predictions seen in the virtual cysts in experiments using real human cells cultivated from polycystic kidneys from patients at the IU School of Medicine.

«We see this mild increase in Aβ42 in cells from patients with Alzheimer's disease, which seems to be enough to trigger disease processes,» said Young - Pearse, a Harvard Stem Cell Institute - affiliated faculty member at Brigham and Women's Hospital.

For instance, researchers at the Salk Institute in California have taken skin cells from a patient with the genetic disease Fanconi's anemia, often associated with leukemia.

The three - year study included cell culture studies at Rice as well as a detailed analysis of gene - expression profiles of more than 500 patients from the Cancer Genome Atlas and protein - expression profiles from about 200 MD Anderson patients.

Further research could test these cancer stem cell gene expression at the RNA and protein level in circulating tumor cells and biopsies from patients on trial.

Cheng, an assistant professor of medicine in hematology / oncology at Feinberg, provided the cell lines and NanoFlare targets the researchers used to model blood samples taken from breast cancer patients.

During an early clinical trial at the Miami Project last year, researchers took Schwann cells from an easily accessible sensory nerve in a patient's leg, grew them in culture and injected them at the point of the spinal cord injury.

Treating the potentially blinding haze of a scar on the cornea might be as straightforward as growing stem cells from a tiny biopsy of the patient's undamaged eye and then placing them on the injury site, according to mouse model experiments conducted by researchers at the University of Pittsburgh School of Medicine.

Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.

«I'm a breast oncologist, and I've seen too many patients die from triple - negative disease,» said senior author Andrei Goga, MD, PhD, professor of cell and tissue biology and of medicine at UCSF, and a member of the Helen Diller Family Comprehensive Cancer Center.

Using cells from Down patients, scientists at the University of Massachusetts Medical School transplanted the XIST gene into that third copy.

Leukemia researchers at Princess Margaret Cancer Centre have developed a 17 - gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment.

Anthony Atala, a surgeon and director of the Institute for Regenerative Medicine at Wake Forest University School of Medicine in Winston - Salem, North Carolina, reported that artificial bladders can be grown in the lab from a patient's own cells and successfully implanted.

Five to seven years down the road, he predicts, patients recovering from spinal fusion or joint - replacement operations will have some of their own fat cells removed, processed, and implanted at the same time as other surgical procedures.

Researchers at the RIKEN Center for Developmental Biology in Kobe plan to generate replacement retinal pigment epithelial cells from iPS cells generated from patients suffering age - related macular degeneration.

Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T cell therapy, through which patients» own T cells were engineered to track down and kill cancer cells that express a tumor - specific protein known as EGFRvIII.